Patents Examined by Howard E. Schain
  • Treatment of inflammation
    Patent number: 5290762
    Abstract: A method for the prophylaxis or direct treatment of inflammatory diseases or injuries in a patient which comprises administering to the site of the disease or injury an effective amount of at least one serine protease inhibitor, its salts, derivatives or analogs which bind with the mast cell mediators, T-cell mediators or kallikrein.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: March 1, 1994
    Inventors: John Lezdey, Allan Wachter
  • Method for reducing atherosclerotic lesions in a mammal
    Patent number: 5290549
    Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for reducing or removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: October 16, 1992
    Date of Patent: March 1, 1994
    Assignee: Genetics Institute, Inc.-Legal Affairs
    Inventor: Marc B. Garnick
  • Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
    Patent number: 5290918
    Abstract: The present invention relates to a process of making a concentrate of coagulation proteins starting with whole human or animal plasma. This concentrate is used as a biological adhesive when extemporaneously mixed to thrombin. The concentrated proteins include mostly fibrinogen, fibrin stabilizing factor (factor XIII) and fibronectin. The claimed process has the advantage of being short of execution while providing an excellent yield of coagulable proteins. No protease inhibitor has to be added during the process. The process involves steps of acidic precipitation in presence of amino-6 hexanoic acid which prevents co-precipitation of plasminogen with the desired coagulable proteins. The proteins so obtained are very stable after reconstitution in water for at least 24 hours at room or body temperature. After mixing with thrombin, the adhesive shows excellent strength and biocompatibility.
    Type: Grant
    Filed: February 23, 1993
    Date of Patent: March 1, 1994
    Assignee: Haemacure Biotech Inc.
    Inventor: Trung Bui-Khac
  • Pharmacologically active substance BPC, the process for its preparation and its use in the therapy
    Patent number: 5288708
    Abstract: A new substance BPC; the process for its preparation from human and animal gastric juice comprising purifications steps: centrifugalization, dialysis, ion-exchange, chromotagraphy, gal chromatography and lyophilisation; a drug for human and veterinary use and a process for the treatment of stress-induced diseases and disorders, inflammation and edemas, diseases and disorders of dopaminergic etiology, for treatment of diabetes mellitus, diseases and disorders of gastrointestinal tract, heart, kidney, pancreas, liver, testis, hematopoetic, skeletal and nervous, system, dementias, wound, burns, fracture, viral diseases, malignancy; in surgery; some disorders of fertility and immune system; protection against ionizing radiation; for veterinary use in commercial breeding.
    Type: Grant
    Filed: May 10, 1991
    Date of Patent: February 22, 1994
    Inventors: Predrag Sikiric, Marijan Petek, Ivo Rotkvic, Stjepan Mise, Simun Krizanac, Ivan Udovicic, Ernest Suchanek, Marko Duvnjak, Jerka Jukic
  • Purification of factor IX
    Patent number: 5286849
    Abstract: The present invention relates to a process for purifying Factor IX from an impure protein fraction containing Factor IX. The purification process comprises the steps of adding a solvent and a detergent to an impure protein fraction and incubating the solvent/detergent protein solution to inactivate any viral contaminants. Factor IX is purified from the solvent/detergent protein solution by chromatography on a sulfated polysaccharide resin without first removing the solvent and detergent prior to the purification on the sulfated polysaccharide resin. The Factor IX, purified by the process has a specific activity of at least 85 units/mg.
    Type: Grant
    Filed: July 14, 1992
    Date of Patent: February 15, 1994
    Assignee: Alpha Therapeutic Corporation
    Inventor: Steven W. Herring
  • Methods of treating cancer using modified C-reactive protein
    Patent number: 5283238
    Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of modified C-reactive protein ("mCRP"). The invention also provides a method of treating cancer in a mammal comprising administering to the mammal mCRP in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, or cytokine. The mCRP may be administered to the mammal in a pharmaceutically-acceptable carrier or in liposomes. The invention further provides a method of identifying cancer cells in a mammal using mCRP as an imaging agent.
    Type: Grant
    Filed: April 24, 1992
    Date of Patent: February 1, 1994
    Assignees: Immtech International, Inc., Northwestern University
    Inventors: Lawrence A. Potempa, John J. Kresl, Byron E. Anderson
  • Serum growth factor
    Patent number: 5281582
    Abstract: A novel glycosylated form of albumin designated EGA and isolated from biological fluids is further characterized by its cell growth promoting activity. A process of isolation of human or bovine glycosylated albumin is described. The EGA fractions have been identified by serological histochemical and biological assays as well as lectin reactivity. The growth-promoting effect of EGA is directed to various transformed cell lines and primary cells of mammalian origin. Hepatoma cells have been found to produce EGA, in vitro. Novel compositions of EGA containing media are provided for cell, tissue or organ culture.
    Type: Grant
    Filed: February 27, 1992
    Date of Patent: January 25, 1994
    Assignee: Alliance Pharmaceuticals, Corp.
    Inventor: Philip Dehazya
  • Calcitonin-containing emulsion for nasal administration
    Patent number: 5281580
    Abstract: The present invention is to provide emulsion preparations for nasal administration containing calcitonins, which are safely and effectively administrated compared with the conventional calcitonin preparations. The emulsions are prepared by using a calcitonin as the active ingredient, an azacycloalkane derivative as the absorption promotor such as 1-[2-(decylthio)ethyl] azacyclopentan-2-one, and glycyrrhizic acid or its salt.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: January 25, 1994
    Assignees: Toyo Jozo Company, Ltd., Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Nakayuki Yamamoto, Michihiko Sugimoto, Hideo Sakakibara, Masaru Saita, Yuji Shimozono, Takafumi Manako
  • Process for producing K-casein glycomacropeptides
    Patent number: 5280107
    Abstract: The present invention provides a process for producing .kappa.-casein glycomacropeptides which comprises contacting milk raw materials containing .kappa.-casein glycomacropeptides having the pH value of 4 or lower with an anion exchanger; collecting by elution of a fraction which adsorbs on the anion exchanger; and concentrating and desalinating the eluted solution to obtain the .kappa.-casein glycomacropeptide.
    Type: Grant
    Filed: January 17, 1992
    Date of Patent: January 18, 1994
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Yoshihiro Kawasaki, Shunichi Dosako, Masaharu Shimatani, Tadashi Idota
  • Process for producing .kappa.-casein glycomacropeptides
    Patent number: 5278288
    Abstract: The present invention provides a process for producing a .kappa.-casein glycomacropeptide comprising contacting milk raw materials containing the .kappa.-casein glycomacropeptide with an ion exchanger; collecting a fraction which does not adsorb on the ion exchanger; and concentrating and desalting the fraction to obtain the .kappa.-casein glycomacropeptide.
    Type: Grant
    Filed: November 26, 1991
    Date of Patent: January 11, 1994
    Assignee: Snow Brand Milk Products Co., Ltd.
    Inventors: Yoshihiro Kawasaki, Shunichi Dosako
  • Method of prophylaxis of acute renal failure
    Patent number: 5273961
    Abstract: A method is disclosed for the prophylactic treatment of mammals at risk for acute renal failure, whether due to renal ischemia or nephrotoxic damage. This method involves administering to the mammal, before or at the time that the acute renal failure is expected to occur or is occurring, an effective amount of IGF-I. Preferably, the IGF-I is native-sequence, mature human IGF-I.
    Type: Grant
    Filed: September 22, 1992
    Date of Patent: December 28, 1993
    Assignee: Genentech, Inc.
    Inventor: Ross G. Clark
  • Process for producing collagen powder
    Patent number: 5274078
    Abstract: A collagen powder is obtained by wet-pulverizing a purified animal tissue consisting mainly of collagen in water at a collagen concentration of 1-30% by weight at a water temperature of not more than 37.degree. C. and a pH value of 2-8, tanning treating the pulverized tissue at a pH level of 2-7 with a polyvalent metal tanning agent to obtain a stabilized wet collagen product, dehydrating the wet collagen product at a pH level of 4-8, and then drying and pulverizing the dehydrated product into a powder. This powder can be used as an additive for modifying paints, artificial leathers, molding materials and the like based on synthetic resins such as thermoplastic resins. The materials obtained with this powder have an excellent appearance, feel, and moisture-absorbing and moisture-releasing properties.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: December 28, 1993
    Assignee: Showa Denko K.K.
    Inventors: Tetsuo Wada, Tetsuhiko Yamaguchi
  • Treatment method of ovarian cancer using interferon gamma
    Patent number: 5268169
    Abstract: A method of treating ovarian cancer in warm-blooded animals comprising intraperitoneally administering to warm-blooded animals by perfusion a recombinant polypeptide of human gamma interferon type with a specific activity at least equal to 1.times.10.sup.7 U/mg in an anti-cancer effective amount.
    Type: Grant
    Filed: April 13, 1992
    Date of Patent: December 7, 1993
    Assignee: Roussel Uclaf
    Inventors: Maud Brandely, Danielle Lando
  • Method for treating a steroid resistant condition via administration of gamma interferon
    Patent number: 5266312
    Abstract: The invention relates to a method for a steroid resistant condition via administration of gamma interferon to a subject, such as a human, afflicted with the condition. The gamma interferon is administered in an amount sufficient to alleviate at least one parameter associated with the steroid resistant condition.
    Type: Grant
    Filed: January 7, 1992
    Date of Patent: November 30, 1993
    Assignee: National Jewis Center for Immunology and Respiratory Medicine
    Inventors: Donald Leung, Stanley Szefler
  • Peptide mixtures
    Patent number: 5266684
    Abstract: A method to obtain selected individual peptides or families thereof which have a target property and optionally to determine the amino acid sequence of a selected peptide or peptides to permit synthesis in practical quantities is disclosed. In general outline, the method of the invention comprises synthesizing a mixture of randomly or deliberately generated peptides using standard synthesis techniques, but adjusting the individual concentrations of the components of a mixture of sequentially added amino acids according to the coupling constants for each amino acid/amino acid coupling. The subgroup of peptides having the target property can then be selected, and either each peptide isolated and sequenced, or analysis performed on the mixture to permit its composition to be reproduced. Also included in the invention is an efficient method to determine the relevant coupling constants.
    Type: Grant
    Filed: May 18, 1990
    Date of Patent: November 30, 1993
    Assignee: The Reagents of the University of California
    Inventors: William J. Rutter, Daniel V. Santi
  • Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
    Patent number: 5260420
    Abstract: The invention provides a thrombin coagulable protein concentrate,, the preparation thereof and the therapeutic use thereof. This concentrate has a fibrinogen content greater than 70% and a sufficient amount of endogenous Factor XIII. It may be solubilized at ambient temperature. Its preparation comprises at least one cold precipitation step with dilute ethanol and uses total plasma as a starting product. The concentrate of the invention makes it possible more particularly to obtain an injectable fibrinogen and a biological glue of high quality.
    Type: Grant
    Filed: April 24, 1992
    Date of Patent: November 9, 1993
    Assignee: Centre Regional de Transfusion Sanguine de Lille
    Inventors: Miryana Burnouf-Radosevich, Thierry Burnouf
  • Stabilization of glycoproteins
    Patent number: 5258501
    Abstract: A process for the preparation of stabilized glycoproteins without the introduction of foreign molecules. Susceptible monosaccharides covalently attached to the protein part of the molecule undergo periodate oxidation and, after elimination of the remaining periodate, the oxidized glycoprotein is incubated in a buffer under conditions favorable for the reaction between the aldehyde groups generated in the sugar part and the amino acid residues from the protein part. The oxidized carbohydrate chains act as a polyaldehyde crosslinker, with the cross-linking reaction producing intramolecularly and intermolecularly linked derivatives. The amount and size of the intermolecularly linked derivatives are controlled by degree of oxidation and protein concentration. The thermal stability, depends on the degree of oxidation and under optimal conditions is about 10 times better than the stability of native invertase.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: November 2, 1993
    Inventors: Slobodan Barbaric, Branko Kozulic
  • Wound healing using IGF-II and TGF
    Patent number: 5256644
    Abstract: Healing an external wound of a mammal by administering to the mammal a composition containing purified Insulin-like growth factor-I and purified transforming growth factor beta.
    Type: Grant
    Filed: March 25, 1992
    Date of Patent: October 26, 1993
    Assignees: Institute of Molecular Biology, Inc., President and Fellows of Harvard College
    Inventors: Harry N. Antoniades, Samuel E. Lynch
  • Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
    Patent number: 5254536
    Abstract: Pharmaceutical compositions for controlling, by topical administration, localized bleeding in a patient, the composition comprising active PAI-1 protein in an amount effective to control the localized bleeding when topically administered, and a vehicle suitable for the topical administration, as well as methods and kits employing the same, are disclosed.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: October 19, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Adrienne L. Racanelli, Thomas M. Reilly
  • Process for the preparation of a pasteurized and iron-free human transferrin and the use thereof
    Patent number: 5252715
    Abstract: A process for the preparation of an iron-free, pasteurized human transferrin is described and entails human transferrin being pasteurized in the presence of a complexing agent in solution, and the complexing agent being removed with the bound iron.This transferrin can be used as pharmaceutical or growth factor.
    Type: Grant
    Filed: December 11, 1991
    Date of Patent: October 12, 1993
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Heinz Haupt